Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESMAVAC-1 malaria vaccine study in healthy children
PACTR201712002879427Not yet recruiting
- Sponsor
- Centre de Recherches Médicales de Lambaréné
- Start
- Mar 2018
- Modality
- Small Molecules, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Trial of Sanaria PfSPZ Vaccine and chloroquine in malaria (4 arms), sponsored by Centre de Recherches Médicales de Lambaréné. Primary endpoint: Occurrence of Grade 3 adverse events and serious adverse events. Planned start Mar 2018; status: not yet recruiting.
02
Drugs
Sanaria PfSPZ Vaccinechloroquine
03
Conditions
malaria
Beyond the preview
Go deeper on PACTR201712002879427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR201712002879427.